[Systemic Lupus Erythematosus and COVID-19]

Area of Science:

• Immunology
• Infectious Diseases
• Rheumatology

Background:

• The COVID-19 pandemic presented unique challenges for managing patients with systemic lupus erythematosus (SLE).
• Understanding the specific risks and clinical course of COVID-19 in SLE patients is crucial for effective care.
• Existing literature provides insights into managing this complex intersection of diseases.

Purpose of the Study:

• To synthesize current knowledge on managing SLE patients during the COVID-19 pandemic.
• To analyze the risks of SARS-CoV-2 infection and COVID-19 severity in SLE individuals.
• To review the role of antiphospholipid antibodies in thrombotic events and discuss adapted treatment strategies.

Main Methods:

• Literature synthesis based on published articles.
• Review of studies focusing on SLE patient management during the COVID-19 pandemic.
• Analysis of data concerning infection risk, clinical presentation, and therapeutic interventions.

Main Results:

• SLE patients may face distinct COVID-19 infection risks and clinical trajectories compared to the general population.
• Antiphospholipid antibodies (aPL) are implicated in increased thrombotic complications in SLE patients with COVID-19.
• Treatment strategies require careful consideration of immunosuppression and potential drug interactions.

Conclusions:

• Optimized management protocols are essential for SLE patients during pandemics.
• Close monitoring and tailored therapeutic approaches are necessary to mitigate adverse outcomes.
• Further research is warranted to refine long-term strategies for managing autoimmune diseases in the context of infectious threats.